WHO Stops The Use Of Hydroxychloroquine


The solidarity trial arm of the World Health Organization (WHO) has stopped the researches into the use of Hydroxychloroquine to effectively treat patients with COVID-19.

It said that several studies have indicated that Hydroxychloroquine (an anti-malaria drug) has no impact whatsoever on the virus, and does not result in the reduction of mortality of hospitalised COVID-19 patients.

This is coming days after U.S Food and Drug Administration (FDA) revoked the emergency authorisation for Hydroxychloroquine to treat hospitalized COVID-19 patients, amidst several evidences that it could cause serious side-effects, and that it does not work.

READ:  WHO Warns On The Use Of Mask During Exercise

It said, “The Solidarity Trial’s Hydroxychloroquine arm is being stopped, on the basis of evidence showing it does not reduce mortality for hospitalised COVID-19 patients.”

On Tuesday, researchers at the University of Oxford in England reported that a commonly used steroid called dexamethasone can help COVID-19 patients on ventilators survive the illness, although the data from that trial have not be made public.

The WHO described the initial clinical trial results from dexamethasone as a welcome development, and can be lifesaving for treating patients who are critically ill with COVID-19.

READ:  Osagie Ize-Iyamu Emerges APC Guber Candidate

It however said it will carry out an in-depth analysis of the intervention with the new drug, before issuing clinical guidance on how and when it should be used.

The WHO made this known yesterday in a statement.



Please enter your comment!
Please enter your name here